161 related articles for article (PubMed ID: 2498468)
41. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
Tomioka H; Sato K; Saito H
Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
[TBL] [Abstract][Full Text] [Related]
42. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
Marinis E; Legakis NJ
J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
[TBL] [Abstract][Full Text] [Related]
43. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.
Stone MS; Wallace RJ; Swenson JM; Thornsberry C; Christensen LA
Antimicrob Agents Chemother; 1983 Oct; 24(4):486-93. PubMed ID: 6651277
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria.
Li G; Pang H; Guo Q; Huang M; Tan Y; Li C; Wei J; Xia Y; Jiang Y; Zhao X; Liu H; Zhao LL; Liu Z; Xu D; Wan K
Int J Antimicrob Agents; 2017 Mar; 49(3):364-374. PubMed ID: 28131606
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
Gatadi S; Gour J; Shukla M; Kaul G; Dasgupta A; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2019 Aug; 175():287-308. PubMed ID: 31096152
[TBL] [Abstract][Full Text] [Related]
46. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
Akselband Y; Cabral C; Shapiro DS; McGrath P
J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
[TBL] [Abstract][Full Text] [Related]
47. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Kaur D; Khuller GK
Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
[TBL] [Abstract][Full Text] [Related]
48. [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria].
Saito H; Sato K; Tomioka H; Watanabe T
Kekkaku; 1987 May; 62(5):287-94. PubMed ID: 3114537
[No Abstract] [Full Text] [Related]
49. Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics.
Nozawa RT; Kato H; Yokota T; Sugi H
Antimicrob Agents Chemother; 1985 Jan; 27(1):132-4. PubMed ID: 3985594
[TBL] [Abstract][Full Text] [Related]
50. Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
Easmon C; Verity L
Eur J Clin Microbiol; 1987 Apr; 6(2):165-6. PubMed ID: 3109896
[TBL] [Abstract][Full Text] [Related]
51. In vitro susceptibility of mycobacteria, especially of Mycobacterium intracellulare, to 5-fluorouracil and pattern of development of resistance of Mycobacterium tuberculosis to the drug.
Tsukamura M
Microbiol Immunol; 1979; 23(5):427-9. PubMed ID: 116112
[No Abstract] [Full Text] [Related]
52. Susceptibilities of Mycobacterium fortuitum biovariant fortuitum and the unnamed third biovariant complex to heavy-metal salts.
Wallace RJ; Steele LC; Forrester GD; Swenson JM; Hull SI
Antimicrob Agents Chemother; 1984 Oct; 26(4):594-6. PubMed ID: 6517549
[TBL] [Abstract][Full Text] [Related]
53. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria.
Ho YI; Chan CY; Cheng AF
J Antimicrob Chemother; 1997 Jul; 40(1):27-32. PubMed ID: 9249201
[TBL] [Abstract][Full Text] [Related]
54. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
55. Osteomyelitis, pericarditis, mediastinitis, and vasculitis due to mycobacterium chelonei.
Jauregui L; Arbulu A; Wilson F
Am Rev Respir Dis; 1977 Apr; 115(4):699-703. PubMed ID: 848795
[No Abstract] [Full Text] [Related]
56. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
[TBL] [Abstract][Full Text] [Related]
57. Therapy of infections caused by 'atypical' mycobacteria.
Grange JM
J Antimicrob Chemother; 1984 Apr; 13(4):308-10. PubMed ID: 6725182
[No Abstract] [Full Text] [Related]
58. In vitro susceptibility of Mycobacterium fortuitum to non-antituberculous antibacterial agents.
Casal MJ; Rodriguez FC
Ann Microbiol (Paris); 1983; 134A(1):73-8. PubMed ID: 6847037
[TBL] [Abstract][Full Text] [Related]
59. Potentiation of the effects of chlorhexidine diacetate and cetylpyridinium chloride on mycobacteria by ethambutol.
Broadley SJ; Jenkins PA; Furr JR; Russell AD
J Med Microbiol; 1995 Dec; 43(6):458-60. PubMed ID: 7473681
[TBL] [Abstract][Full Text] [Related]
60. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.
Swenson JM; Thornsberry C; Silcox VA
Antimicrob Agents Chemother; 1982 Aug; 22(2):186-92. PubMed ID: 6927280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
